Product Description:
Riamet Tab 20/120mg is a combination antimalarial medication containing two active ingredients: Artemether (20mg) and Lumefantrine (120mg). This pharmaceutical product is designed to provide effective treatment against Plasmodium falciparum, the parasite responsible for the most severe form of malaria. The dual-action formula targets the parasite at various stages of its life cycle, ensuring comprehensive eradication and symptom relief.
Technician Specifications:
- Composition: Each tablet contains 20mg of Artemether and 120mg of Lumefantrine.
- Dosage Form: Oral tablet.
- Packaging: Blister packs containing 24 tablets.
- Storage: Store below 30°C (86°F) and protect from moisture.
- Shelf Life: Check the packaging for the expiration date; do not use beyond this date.
- Administration: To be taken as directed by a healthcare professional, typically in a dosing schedule over a 3-day period.
Common Applications/User Groups:
- Indicated Users: Patients diagnosed with uncomplicated Plasmodium falciparum malaria.
- Geographical Relevance: Particularly useful in regions with high rates of malaria or for travelers to endemic areas.
- Age Restrictions: Suitable for adults and children weighing 5 kg (11 lbs) and above, with dosing adjusted for weight.
Supplier Overview - Novartis:
Novartis is a global healthcare company that stands as a leader in the research and development of innovative medicines. With a strong commitment to addressing complex health challenges, Novartis has established itself as an authority in the field of antimalarial treatments. Their dedication to improving patient outcomes and expanding access to essential medications in developing countries underscores their expertise and reliability in the pharmaceutical industry. Novartis' investment in cutting-edge research and adherence to stringent quality control measures ensures that products like Riamet Tab 20/120mg are both safe and effective for combating malaria.